WO1994028145A3 - Expression of urokinase plasminogen activator inhibitors - Google Patents

Expression of urokinase plasminogen activator inhibitors Download PDF

Info

Publication number
WO1994028145A3
WO1994028145A3 PCT/US1994/005669 US9405669W WO9428145A3 WO 1994028145 A3 WO1994028145 A3 WO 1994028145A3 US 9405669 W US9405669 W US 9405669W WO 9428145 A3 WO9428145 A3 WO 9428145A3
Authority
WO
WIPO (PCT)
Prior art keywords
expression
plasminogen activator
urokinase plasminogen
activator inhibitors
hupar
Prior art date
Application number
PCT/US1994/005669
Other languages
French (fr)
Other versions
WO1994028145A2 (en
Inventor
Steven Rosenberg
Jennifer R Stratton-Thomas
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to AU71379/94A priority Critical patent/AU7137994A/en
Priority to KR1019950705328A priority patent/KR960702522A/en
Priority to DE69432608T priority patent/DE69432608T2/en
Priority to JP7500817A priority patent/JPH08508172A/en
Priority to AT94920676T priority patent/ATE239085T1/en
Priority to EP94920676A priority patent/EP0802983B1/en
Publication of WO1994028145A2 publication Critical patent/WO1994028145A2/en
Publication of WO1994028145A3 publication Critical patent/WO1994028145A3/en
Priority to NO954778A priority patent/NO954778L/en
Priority to FI955721A priority patent/FI955721A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Unfucosylated huPAR polypeptides that contains huPA1-48 (SEQ ID NQ:22) are provided. These polypeptides are useful for treating diseases wherein antagonism of huPAR is therapeutically beneficial.
PCT/US1994/005669 1993-06-01 1994-05-19 Expression of urokinase plasminogen activator inhibitors WO1994028145A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU71379/94A AU7137994A (en) 1993-06-01 1994-05-19 Expression of urokinase plasminogen activator inhibitors
KR1019950705328A KR960702522A (en) 1993-06-01 1994-05-19 Expression of urokinase plasminogen activator inhibitors (EXPRESSION OF UROKINASE PLASMINOGEN ACTIVATOR INHIBITORS)
DE69432608T DE69432608T2 (en) 1993-06-01 1994-05-19 EXPRESSION OF INHIBITORS OF THE PLASMINOGEN ACTIVATOR OF THE UROKINASE TYPE
JP7500817A JPH08508172A (en) 1993-06-01 1994-05-19 Expression of urokinase plasminogen activator inhibitor
AT94920676T ATE239085T1 (en) 1993-06-01 1994-05-19 EXPRESSION OF UROKINASE TYPE PLASMINOGEN ACTIVATOR INHIBITORS
EP94920676A EP0802983B1 (en) 1993-06-01 1994-05-19 Expression of urokinase plasminogen activator inhibitors
NO954778A NO954778L (en) 1993-06-01 1995-11-24 Expression of urokinase plasminogen activator inhibitors
FI955721A FI955721A (en) 1993-06-01 1995-11-27 Expression of inhibitors for a urokinase-type plasminogen activator

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7015393A 1993-06-01 1993-06-01
US08/070,153 1993-06-01

Publications (2)

Publication Number Publication Date
WO1994028145A2 WO1994028145A2 (en) 1994-12-08
WO1994028145A3 true WO1994028145A3 (en) 1995-10-19

Family

ID=22093474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/005669 WO1994028145A2 (en) 1993-06-01 1994-05-19 Expression of urokinase plasminogen activator inhibitors

Country Status (12)

Country Link
US (1) US6268341B1 (en)
EP (1) EP0802983B1 (en)
JP (1) JPH08508172A (en)
KR (1) KR960702522A (en)
AT (1) ATE239085T1 (en)
AU (1) AU7137994A (en)
CA (1) CA2162855A1 (en)
DE (1) DE69432608T2 (en)
FI (1) FI955721A (en)
NO (1) NO954778L (en)
NZ (1) NZ268470A (en)
WO (1) WO1994028145A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519120A (en) * 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
KR960702522A (en) 1993-06-01 1996-04-27 로버트 피. 블랙버언 Expression of urokinase plasminogen activator inhibitors (EXPRESSION OF UROKINASE PLASMINOGEN ACTIVATOR INHIBITORS)
US5891742A (en) * 1995-01-19 1999-04-06 Chiron Corporation Affinity selection of ligands by mass spectroscopy
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
WO1999020295A1 (en) * 1997-10-17 1999-04-29 Trustees Of The University Of Pennsylvania Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
US6750201B1 (en) 1997-10-17 2004-06-15 The Trustees Of The University Of Pennsylvania Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
DE69921102T2 (en) * 1998-03-05 2006-02-02 Chiron Corp., Emeryville METHOD FOR IMPROVING THE SERUM HALF-TIME OF BIOLOGICALLY ACTIVE MOLECULES
US6077508A (en) * 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
US20030203032A1 (en) * 2002-04-25 2003-10-30 Schultz Clyde L. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
EP1503730A4 (en) * 2002-04-25 2005-09-28 Rapidheal Inc Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007083A1 (en) * 1990-10-18 1992-04-30 Cancerforskningsfondet Af 1989 Antibodies against the urokinase receptor and their use
WO1994022464A1 (en) * 1993-04-02 1994-10-13 The General Hospital Corporation Urokinase plasminogen activator fragments

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112755A (en) 1982-04-15 1992-05-12 Genentech, Inc. Preparation of functional human urokinase proteins
US4870008A (en) * 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
US4791068A (en) 1984-06-22 1988-12-13 Scripps Clinic And Research Foundation Diagnostic assay for inhibitor of tissue-type and urokinase-type plasminogen activators
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0218696A4 (en) 1985-04-15 1989-08-16 Biotech Res Partners Ltd Human anti-inflammatory phospholipase inhibitor protein.
US5219569A (en) 1985-04-22 1993-06-15 Genentech, Inc. Protease resistant urokinase
US5376547A (en) 1987-01-30 1994-12-27 American Home Products Corporation Des-epidermal growth factor plasminogen activators
US4835255A (en) 1987-03-26 1989-05-30 Yale University T-cell membrane protein
US4999194A (en) 1988-01-14 1991-03-12 Collaborative Research, Inc. Two-chain urokinase plasminogen activators for treatment of thrombotic disease
DK182289D0 (en) 1989-04-14 1989-04-14 Francesco Blasi MODIFICATION OF PROTEINS
JPH0595786A (en) 1991-10-07 1993-04-20 Green Cross Corp:The Mutant human prourokinase
US5340833A (en) 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
AU682877B2 (en) * 1993-05-28 1997-10-23 Chiron Corporation Peptide inhibitors of urokinase receptor activity
KR960702522A (en) 1993-06-01 1996-04-27 로버트 피. 블랙버언 Expression of urokinase plasminogen activator inhibitors (EXPRESSION OF UROKINASE PLASMINOGEN ACTIVATOR INHIBITORS)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007083A1 (en) * 1990-10-18 1992-04-30 Cancerforskningsfondet Af 1989 Antibodies against the urokinase receptor and their use
WO1994022464A1 (en) * 1993-04-02 1994-10-13 The General Hospital Corporation Urokinase plasminogen activator fragments

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 2092, Derwent World Patents Index; Class B04, AN 92-167162 *
E. APPELLA ET AL: "The receptor-binding sequence of urokinase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 262, no. 10, 5 April 1987 (1987-04-05), MD US, pages 4437 - 4440 *
H. LOWMAN ET AL: "Selecting high-affinity binding proteins by monovalent phage display", BIOCHEMISTRY, vol. 30, pages 10832 - 10838 *
K. FREDERICK ET AL: "Glucose oxidase from Aspergillus niger", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 7, 5 March 1990 (1990-03-05), MD US, pages 3793 - 3802 *
S. KINGSMAN AND A. KINGSMAN: "Genetic engineering", BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD *
S. RABBANI ET AL: "Structural requirements for the growth factor activity of the aminoterminal domain of urokinase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 20, 15 July 1992 (1992-07-15), MD US, pages 14151 - 14156 *

Also Published As

Publication number Publication date
DE69432608T2 (en) 2004-02-26
CA2162855A1 (en) 1994-12-08
FI955721A0 (en) 1995-11-27
WO1994028145A2 (en) 1994-12-08
DE69432608D1 (en) 2003-06-12
EP0802983B1 (en) 2003-05-02
FI955721A (en) 1995-11-27
EP0802983A2 (en) 1997-10-29
NO954778D0 (en) 1995-11-24
ATE239085T1 (en) 2003-05-15
NZ268470A (en) 1997-09-22
KR960702522A (en) 1996-04-27
US6268341B1 (en) 2001-07-31
NO954778L (en) 1995-11-24
AU7137994A (en) 1994-12-20
JPH08508172A (en) 1996-09-03

Similar Documents

Publication Publication Date Title
WO1994028145A3 (en) Expression of urokinase plasminogen activator inhibitors
MY119155A (en) New peptide derivatives
GB8909919D0 (en) Small polypeptides
NZ309523A (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders
MX9706069A (en) Novel dipeptide amidines as thrombin inhibitors.
CA2068320A1 (en) Production of recombinant human interleukin-1 inhibitor
HK1002457A1 (en) Angiostatin fragments and methods of use
MY111201A (en) New imidazopyridines
AU5846494A (en) Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
AU6458396A (en) Phosphorous-containing cysteine and serine protease inhibitors
UA27910C2 (en) Method of increasing thrombomodulin expression and increasing protein c activation rate
UA27132C2 (en) TWO-FUNCTIONAL UROKINASE VARIANTS WITH BIASED FIBRINOLYTIC activity and thrombin-inhibitory action
AU1778988A (en) Novel fibrinolytic enzymes
EP0643075A4 (en) Novel peptide having elastase inhibitor activity and process for producing the same.
IL111501A0 (en) Pharmaceutical compositions comprising lys-plasminogen and tissue plasminogen activator (t-PA) for the treatment of coronary thrombosis
AU6739096A (en) Use of plasminogene activators to stimulate local bone growth
MX9709340A (en) IMIDAZO[1,5a]PYRIDINE DERIVED SERINE PROTEASE INHIBITORS.
AU6251594A (en) Treatment of cancerous growths with biologically active peptides and protease inhibitors
NZ332903A (en) Angiostatin fragments and aggregate angiostatin and methods for inhibiting endothelial cell proliferation
HU903267D0 (en) Process for the production of tissue-plasmingen-activator
EP0292326A3 (en) Modified enzyme
FI102844B1 (en) Process for the preparation of an improved therapeutically active activator for tissue plasminogen
AU4390597A (en) Combination therapy for treatment of arthritic diseases
IL117761A0 (en) Inhibitor of the erythrina caffra type and its use to purify serine proteases
AU4856890A (en) Process and intermediates for isopropyl 3s-amino-2r-hydroxy- alkanoates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 268470

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2162855

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 955721

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1994920676

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1994920676

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994920676

Country of ref document: EP